We are live on ! Find out more
PSTX

Poseida Therapeutics, Inc. Common Stock
PSTX

Delisted

PSTX was delisted on the 7th of January, 2025.

Back to rankings

52 hedge funds and large institutions have $213M invested in Poseida Therapeutics, Inc. Common Stock in 2020 Q3 according to their latest regulatory filings, with 52 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
52
Holders Change
+52
Holders Change %
–
% of All Funds
1.05%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
52
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$106M
2
PCM
Pentwater Capital Management
Florida
+$55.5M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$15.4M
4
BC
Boxer Capital
California
+$14.2M
5
SAM
Sectoral Asset Management
Quebec, Canada
+$12M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Goldman Sachs
26
Goldman Sachs
New York
$322K +$413K +36,272 New
CCM
27
CAAS Capital Management
New York
$222K +$284K +25,000 New
BFM
28
Boothbay Fund Management
New York
$221K +$284K +24,943 New
Bank of New York Mellon
29
Bank of New York Mellon
New York
$206K +$265K +23,292 New
N
30
Nuveen
North Carolina
$199K +$255K +22,428 New
California State Teachers Retirement System (CalSTRS)
31
California State Teachers Retirement System (CalSTRS)
California
$180K +$231K +20,321 New
Norges Bank
32
Norges Bank
Norway
$177K +$228K +20,000 New
RIL
33
Rothschild Investment LLC
Illinois
$160K +$205K +18,000 New
DKCM
34
Davidson Kempner Capital Management
New York
$106K +$137K +12,000 New
Squarepoint
35
Squarepoint
New York
$100K +$128K +11,265 New
ZP
36
Zimmer Partners
New York
$98K +$125K +11,000 New
Bank of America
37
Bank of America
North Carolina
$93K +$120K +10,570 New
Qube Research & Technologies (QRT)
38
Qube Research & Technologies (QRT)
United Kingdom
$91K +$117K +10,309 New
PSC
39
Piper Sandler & Co
Minnesota
$74K +$94.4K +8,298 New
AIG
40
American International Group
New York
$71K +$91.4K +8,030 New
Deutsche Bank
41
Deutsche Bank
Germany
$60K +$76.6K +6,732 New
JP Morgan Chase
42
JP Morgan Chase
New York
$45K +$57K +5,006 New
Wells Fargo
43
Wells Fargo
California
$37K +$47.4K +4,166 New
SO
44
STRS Ohio
Ohio
$30K +$38.7K +3,400 New
TRCT
45
Tower Research Capital (TRC)
New York
$22K +$27.8K +2,446 New
Morgan Stanley
46
Morgan Stanley
New York
$18K +$23.6K +2,074 New
Legal & General Group
47
Legal & General Group
United Kingdom
$13K +$16.7K +1,466 New
AIP
48
Ameritas Investment Partners
Nebraska
$10K +$13K +1,144 New
Bank of Montreal
49
Bank of Montreal
Ontario, Canada
$6K +$7.09K +623 New
Citigroup
50
Citigroup
New York
$6K +$7.34K +645 New
1
2
3

PSTX Hedge Fund Activity: Q3 2020 in Review

52 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Poseida Therapeutics, Inc. Common Stock (PSTX) for Q3 2020, worth a combined $213M.

Buyers outnumbered sellers: 52 funds opened new PSTX positions and 0 closed out — a net gain of 52 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Fidelity Investments, opening a new position worth an estimated $106M.

  • 52 institutional investors held Poseida Therapeutics, Inc. Common Stock (PSTX) as of Q3 2020, up from 0 in Q2 2020.
  • Funds reported $213M of Poseida Therapeutics, Inc. Common Stock stock for Q3 2020.
  • 52 funds opened new Poseida Therapeutics, Inc. Common Stock positions in Q3 2020 and 0 closed out, a net change of +52 holders.
  • The largest Poseida Therapeutics, Inc. Common Stock buyer in Q3 2020 was Fidelity Investments, an estimated $106M added.

Based on aggregated 13F filings for Q3 2020.